Navigation Links
Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
Date:4/29/2013

OXFORD, England, April 29, 2013 /PRNewswire/ --

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim

(BI) today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.

Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications. Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.

OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.

Christian Rohlff , CEO of OBT, commented: "Selecting the right target is fundamental for the successful development of a first in class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development."

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on delivering innovative and cost-effective first-in-class medicines to fulfil major unmet patient needs in the field of cancer. OBT is developing cutting-edge antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered through its unique OGAP® proteomic database. OGAP® represents the world's largest proprietary collections of disease-associated proteins. It contains proteomic data on over 7,500 cancer membrane proteins and proprietary protein disease expression information more than three-qu
'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oxford Performance Materials and Biomet Microfixation Join Forces
2. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
3. Oxford Finance Completes $271.4 Million Securitization Transaction
4. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
5. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
6. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
7. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... has named Todd Creech as Chief Financial Officer and ... Creech has been fulfilling both positions as a consultant ... http://photos.prnewswire.com/prnh/20110214/FL47222LOGO ) "Todd comes to ... leadership roles and has demonstrated great success in helping ...
... Even with radical advances in medicine and technology ... penile extender system is still the most effective ... QuickExtenderPro.com, the leading provider of penis extender ... With the emergence of the penile extender, procedures such ...
... EXTON, Pa., Feb. 11, 2011 ViroPharma Incorporated (Nasdaq: ... chief executive officer of ViroPharma, will present at the Leerink ... ET on Thursday, February 17, 2011.  The conference is being ... ViroPharma,s presentations will be webcast live for investors through ...
Cached Biology Technology:Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 2Todd A. Creech Named Chief Financial Officer and Vice President of Business Development for SARcode Corporation 3QuickExtenderPro.com Penis Extender Device Engineered for Quick, Safe and Effective Alternative to Penis Enlargement Surgery 2ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference 2
(Date:4/18/2014)... techniques like X-ray crystallography and nuclear magnetic resonance imaging ... of molecules, but such efforts have long been hampered ... a specific molecule and often in ordered and crystalized ... impossible to peer into the structure of most molecules. ... be a thing of the past. , A ...
(Date:4/18/2014)... and comet impacts can cause widespread ecological havoc, killing ... scales. But new research from Brown University shows that ... at the time of an impact. , A research ... fragments of leaves and preserved organic compounds lodged inside ... The material could provide a snapshot of environmental conditions ...
(Date:4/17/2014)... chili peppers. Information about archaeological remains of ancient chili ... appearance of words for chili peppers in ancient dialects ... highlight the value of multi-proxy data analysis. Their results ... papers presented in a special feature issue of the ... on plant and animal domestication edited by Dolores Piperno, ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Chickens to chili peppers 2Chickens to chili peppers 3
... Earthwatch met in Panama from Mar. 1-5 to present mid-term ... to identify and respond to the impacts of climate change. ... global team of bank employees ,climate champions, in ... program of its kind has so far: , Found ...
... $10.2 million commitment from the Robertson Foundation to create ... Duke Medicine,s pioneering cell therapy research and treatment programs ... and brain injuries suffered at birth. In making the ... Duke University, and Chief Executive Officer for Duke University ...
... medicine is one of today,s most exciting scientific and ... ,firsts, new rulings by regulatory bodies or ethical controversies. ... field, ethicists, legislators, the media and the public. ... are open to journalists and registration is free to ...
Cached Biology News:HSBC Climate Partnership yields initial research findings 2HSBC Climate Partnership yields initial research findings 3Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 2Robertson Foundation donates $10.2 million for Duke Cell Therapy Center 3ESHRE Annual Meeting, June 27-30 in Rome 2
... Cell Receptor-P1, clone 1C10 ... Hybridoma produced by the fusion ... immunized (BALB/c X C57BL/6)F1 (CbyB6F1) ... mouse myeloma cellline. ...
... Mouse monoclonal [YPF19] to Yersinia pestis ... detect Yersinia pestis . ... Yersinia pestis vaccine strain ... antibody recognises Y.pestis F1 capsular antigen. ...
Rabbit polyclonal to ZFP200 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGKSFNHKTNLNKHER (Human) Entrez Gene ID: 7752 Swiss Protein ID: P98182...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Biology Products: